Lupin Limited has announced that its greenhouse gas emission reduction targets have been formally validated by the Science Based Targets initiative (SBTi), covering Scope 1, Scope 2, and Scope 3 emissions. The validation confirms alignment with the Paris Agreement’s objective of limiting global temperature rise to 1.5°C and places Lupin among a select group of companies to achieve full-scope validation within a year of setting its targets.
Under its approved targets, Lupin aims to cut absolute Scope 1 and Scope 2 emissions by 42 percent by FY 2030 compared to a FY 2023 baseline. The company also plans to reduce Scope 3 emissions by 61.07 percent by FY 2033, addressing emissions across purchased goods and services, logistics, energy-related activities, travel, commuting, product use, and franchises, using FY 2024 as the reference year.
Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, said the validation reflects the company’s science-led approach to sustainability. He noted that the targets are embedded into Lupin’s financial and operational planning, guiding investments in renewable energy, energy efficiency, and low-carbon technologies across its global footprint.
Lupin Limited is a leading global pharmaceutical company headquartered in Mumbai, India, known for its broad portfolio of branded and generic medicines, complex generics, and active pharmaceutical ingredients (APIs). With a strong presence in key markets including the United States, India, Japan, and Europe, Lupin develops and manufactures high-quality healthcare solutions across multiple therapeutic areas such as cardiology, diabetology, central nervous system disorders, respiratory, and anti-infectives. The company combines cutting-edge science, innovation, and robust quality standards to deliver affordable and accessible medications to millions of patients worldwide.
Lupin’s integrated operations span research and development, manufacturing, and global supply chain capabilities, supported by state-of-the-art facilities and a highly skilled workforce. The company has a significant footprint in biosimilars and specialty products and continues to invest in novel therapies and technology platforms to address evolving medical needs. Sustainability and ethical practices are central to Lupin’s operations, with initiatives focused on environmental stewardship, patient safety, and community health.
Driven by a commitment to improve patient outcomes and enhance global healthcare, Lupin leverages deep therapeutic expertise and strategic partnerships to expand its reach and impact. The company’s mission is to deliver innovative, high-quality medicines that make a meaningful difference in people’s lives.
